Table 6 Pharmacological treatment of IPF in the years 2002 – 2016a
From: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Medication | N / % |
|---|---|
No medication | 42 / 31.8 |
Total | |
Corticosteroids | 75 / 56.8 |
Azathioprine | 28 / 37.2 |
N-acetylcysteine | 30 / 40.0 |
Cyclophosphamide | 16 / 12.1 |
Pirfenidone | 6 / 4.5 |
Nintedanib | 3 / 2.3 |
Mycophenolate mofetil | 1 / 0.8 |
Single medication | |
Corticosteroids | 24 / 18.2 |
N-acetylcysteine | 11 / 8.3 |
Pirfenidone | 5 /3.8 |
Nintedanib | 1 /0.8 |
Triple therapy b | 7 /5.3 |
Combined with prednisone as only medication | |
Azathioprine | 14 / 10.6 |
N-acetylcysteine | 13 / 9.8 |
Cyclophosphamide | 8 / 6.1 |
After prednisone therapy | |
Nintedanib | 2 /1.5 |
Before triple therapy | |
Cyclophosphamide + Corticosteroids | 2 / 1.5 |
After triple therapy | |
Pirfenidone | 1 / 0.8 |
Cyclophosphamide | 3 / 2.3 |
Mycophenolate | 1 / 0.8 |